Madrigal Pharmaceuticals (MDGL) PT Raised to $739 at Citizens Before Q2 Results
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $739.00 (from $737.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
